Hypothesis

NAD+ decline during intermittent fasting functions as a signaling cue that triggers a protective metabolic state, whereas constant NAD+ elevation blunts this cue and prevents the hormetic benefits of fasting.

Mechanistic Insight

During fasting, NAD+ falls in specific tissues (muscle, adipose, hippocampus) [3]. This drop reduces substrate for PARP1, limiting NAD+ consumption and freeing NAD+ for sirtuin activation. Sirt1 deacetylates PGC‑1α and FoxO3, promoting mitochondrial biogenesis and stress resistance. Simultaneously, low NAD+ attenuates CD38 activity, curbing the inflammation‑driven NAD+ sink described in the senescence‑inflammation loop [1]. The resulting NAD+ oscillation creates a window where sirtuin signaling dominates over PARP‑CD38 consumption, fostering a transient, adaptive suppression of the senescence‑associated secretory phenotype [4]. When NAD+ is continuously supplemented, the oscillation is dampened; PARP1 remains active due to persistent DNA‑damage signals, CD38 stays elevated, and sirtuin activation becomes sub‑optimal because the enzyme’s affinity for NAD+ is saturable and subject to feedback inhibition. Thus, the system interprets sustained high NAD+ as a fed state, suppressing the fasting‑induced transcriptional program that would otherwise extend healthspan.

Testable Predictions

1. In mice undergoing alternate‑day fasting, tissue‑specific NAD+ levels will show a clear nadir during the fasted phase and a peak during refeeding, correlating with increased Sirt1 activity and decreased PARP1‑CD38 activity.
2. Mice receiving chronic NAD+ precursor (e.g., NR) supplementation alongside the same fasting regimen will exhibit blunted NAD+ oscillations, attenuated Sirt1 activation, and no improvement—or a worsening—of insulin sensitivity and ketone production compared with fasting‑only controls.
3. Genetic disruption of circadian NAD+ biosynthesis (e.g., liver‑specific Nampt knockout) will abolish the fasting‑induced NAD+ nadir and eliminate the hormetic benefits of intermittent fasting, even if NAD+ levels are artificially kept constant via supplementation.

Experimental Design

• Cohorts: Wild‑type C57BL/6 mice (n=10 per group) assigned to: (a) ad libitum fed, (b) alternate‑day fasting (ADF), (c) ADF + NR supplementation (300 mg/kg/day), (d) liver‑specific Nampt KO + ADF, (e) liver‑specific Nampt KO + ADF + NR.
• Measurements: Every 4 h over a 48‑h cycle collect blood for β‑hydroxybutyrate, glucose, insulin; harvest liver, muscle, adipose, hippocampus for NAD+ quantification (LC‑MS), Sirt1 activity (fluorometric deacetylase assay), PARP1 activity (PAR ELISA), CD38 activity (cyclic ADP‑ribose assay), and SASP cytokine profiling (IL‑6, IL-1β).
• Outcome: Compare NAD+ amplitude (peak‑trough difference) and downstream signaling across groups. Expect a significant NAD+ oscillation in group (b) with heightened Sirt1/PARP1 ratio; group (c) showing reduced oscillation and downstream signaling; groups (d) and (e) lacking oscillation and showing minimal metabolic improvement despite NAD+ levels.

Falsifiability

If chronic NAD+ supplementation does not diminish NAD+ oscillation amplitude, or if it enhances Sirt1 activity and metabolic markers equally to fasting alone, the hypothesis would be falsified. Likewise, if liver‑specific Nampt KO mice still display improved insulin sensitivity and ketone production under ADF despite absent NAD+ nadir, the mechanistic link between NAD+ oscillations and hormesis would be refuted.